Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last CNY69.68 CNY
Change Today -1.77 / -2.48%
Volume 999.9K
As of 2:00 AM 03/6/15 All times are local (Market data is delayed by at least 15 minutes).

jiangxi boya bio-pharmaceu-a (300294) Snapshot

Open
CNY71.58
Previous Close
CNY71.45
Day High
CNY71.87
Day Low
CNY69.59
52 Week High
12/2/14 - CNY78.87
52 Week Low
04/28/14 - CNY39.98
Market Cap
5.3B
Average Volume 10 Days
1.4M
EPS TTM
CNY1.37
Shares Outstanding
75.8M
EX-Date
--
P/E TM
50.9x
Dividend
CNY0.60
Dividend Yield
0.72%
Current Stock Chart for JIANGXI BOYA BIO-PHARMACEU-A (300294)

Related News

No related news articles were found.

jiangxi boya bio-pharmaceu-a (300294) Related Businessweek News

No Related Businessweek News Found

jiangxi boya bio-pharmaceu-a (300294) Details

Jiangxi Boya Bio-Pharmaceutical Company Limited researches, develops, produces, and distributes blood products in China. The company’s products include human albumin, freeze-drying intravenous injection human immune globulin, human immune globulin, hepatitis B human immune globulin, hydrophobia human immune globulin, human fibrinogen, and others. Its albumin products are used in the therapy of tumor, liver disease, and diabetes mellitus; and immune globulin products are used in the therapy of immunity and infection diseases. The company also exports its products to India, Southeast Asia, and South America. Jiangxi Boya Bio-Pharmaceutical Company Limited was founded in 1993 and is based in Fuzhou, China.

Founded in 1993

jiangxi boya bio-pharmaceu-a (300294) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

jiangxi boya bio-pharmaceu-a (300294) Key Developments

Jiangxi Boya Bio-Pharmaceutical Co., Ltd Approves Dividend for 2014

Jiangxi Boya Bio-Pharmaceutical Co. Ltd. approved cash dividend per 10 shares (tax included) of CNY 6 for 2014 at the Annual General Meeting held on 03 March 2015.

Jiangxi Boya Bio-Pharmaceutical Co., Ltd Provides Earnings Guidance for the First Quarter of 2015

Jiangxi Boya Bio-Pharmaceutical Co. Ltd. expected net profit of CNY 45 million to CNY 50 million in the first quarter of 2015, rising 133.56% to 159.51% from a year earlier.

Jiangxi Boya Bio-Pharmaceutical Co., Ltd, 2014 Earnings Call, Feb 26, 2015

Jiangxi Boya Bio-Pharmaceutical Co., Ltd, 2014 Earnings Call, Feb 26, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
300294:CH CNY69.68 CNY -1.77

300294 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Beijing Tiantan Biological Products Corp Ltd CNY30.71 CNY -0.87
China Biologic Products Inc $82.88 USD +1.08
Hualan Biological Engineering Inc CNY37.40 CNY -0.60
Shanghai RAAS Blood Products Co Ltd CNY52.90 CNY -0.96
View Industry Companies
 

Industry Analysis

300294

Industry Average

Valuation 300294 Industry Range
Price/Earnings 50.4x
Price/Sales 12.1x
Price/Book 6.1x
Price/Cash Flow 50.2x
TEV/Sales 11.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact JIANGXI BOYA BIO-PHARMACEU-A, please visit www.china-boya.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.